AI Startup BrightHeart Secures €11M To Transform Detection Of World’s Most Common Birth Defect
BrightHeart, a global entity specializing in artificial intelligence (AI) for prenatal ultrasound, has concluded an €11 million Series A financing round.
BrightHeart, a global entity specializing in artificial intelligence (AI) for prenatal ultrasound, has concluded an €11 million Series A financing round.
This funding was co-led by Odyssée Venture and GO Capital. Other participants included the Mussallem CHD Alliance, Lift Value, IDAHO HealthTech Club via Side Angels, and founding investor Sofinnova Partners, alongside notable clinicians and angel investors.
The financing aims to facilitate U.S. commercialization, expand operations in Europe, and foster product innovation. This will enable the scaling of the B-Right AI Platform to establish a new global standard in prenatal ultrasound. BrightHeart's solutions provide expert-level screening for complex organs, aiding OB-GYNs in detecting congenital defects and improving neonatal care.
The platform integrates seamlessly into existing workflows, enabling clinicians to perform more accurate exams, expedite evaluations, and enhance diagnostic confidence without disrupting care delivery.
BrightHeart, a global entity specializing in artificial intelligence (AI) for prenatal ultrasound, has concluded an €11 million Series A financing round.
In 2025, BrightHeart achieved significant milestones, including five FDA clearances and partnerships with leading academic centers, alongside two peer-reviewed publications in Obstetrics & Gynecology. This positions BrightHeart as the sole entity in the field with published peer-reviewed clinical evidence.
The company is poised for global expansion with its unique platform, regulatory foundation, and increasing demand for AI-driven solutions in prenatal imaging. The new funding supports BrightHeart's aim to make AI a standard of care, enhancing diagnostic accuracy and streamlining clinical workflows.
Odyssée Venture and GO Capital, the co-lead investors, have extensive experience in supporting the growth of healthcare technologies. The Mussallem CHD Alliance's participation underscores BrightHeart's role in transforming outcomes for CHD patients.
Based on reporting by techround.co.uk.
